Overview
Roger E. Susi, who holds the roles of CEO, President and Chairman at Iradimed Corporation (NASDAQ: IRMD), reported the sale of 7,400 common shares on March 30, 2026, in a Form 4 filing with the SEC. The disposition was executed under a pre-arranged Rule 10b5-1 trading plan and generated total proceeds of $712,614.
Transaction specifics
The position was sold in three separate tranches, with execution prices spanning from $94.36 to $97.16 per share. The filing breaks down the sales as follows:
- 5,848 shares sold at a weighted average price of $94.81
- 1,497 shares sold at a weighted average price of $95.66
- 155 shares sold at a weighted average price of $96.53
At the time of reporting, IRADIMED’s stock was trading at $96.44, placing it near a 52-week high of $107.90. Over the trailing 12 months the stock has returned 83%.
Valuation signals referenced
The company’s trailing price-to-earnings ratio is noted at 55. Analysis cited in the filing indicates this P/E is high relative to near-term earnings growth, and a platform-level Fair Value assessment referenced in the disclosure suggests the shares may be overvalued at current levels.
Insider holdings following the sale
Post-transaction ownership positions tied to Susi remain substantial. The filing lists indirect holdings as follows:
- 2,225,000 shares through the Phillip Susi 2008 Dynasty Trust
- 162,950 shares through the Roger E. Susi Revocable Trust
- 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust
Context from company results
Separately, Iradimed reported fourth-quarter 2025 results that surpassed analyst expectations. The company delivered earnings per share and revenue figures above consensus estimates for the period. Those results drew investor attention and coincided with a positive reaction in pre-market trading. While specific analyst upgrades or downgrades were not detailed in the disclosure, the stronger-than-expected quarterly performance was highlighted as a factor supporting investor interest.
Research availability
The filing also notes that a comprehensive Pro Research Report covering Iradimed and more than 1,400 other U.S. equities is available on InvestingPro for investors seeking further valuation and performance details.
Investors and market participants will likely continue to watch Iradimed’s trading, valuation metrics and subsequent company updates closely given the combination of insider activity, recent quarterly outperformance and elevated P/E levels.